Histogenics
Waltham, US · Delaware corporation · 3 known investors
Founders & leadership
AG
Adam GridleyExecutive
PG
Peter GreenleafExecutive
Board
JB
Joshua BaltzellBoard director
KR
Kevin RakinBoard director
GK
Garheng Kong, M.D., Ph.D.Board director
GK
Garheng Kong, M.D., Ph.DBoard director
JJ
John J. JohnsonBoard director
DG
David GillBoard director
JL
Jonathan LieberBoard director
ML
Michael LewisBoard director
JJ
John JohnsonBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$54.6M disclosed across 4 rounds · 2013–2020
▶$395raisedMay 2020 · 1 investors · BiotechnologyRule 506(b)
▶$395raisedMay 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Manish PottiDirector
- Sanjay SubramanianExecutive Officer
- Suha TaspolatogluDirector
- Shankar MusunuriExecutive Officer, Director
- Daniel JorgensenExecutive Officer
- Prabhavathi FernandesDirector
- Kristen CastilloDirector
- Ramesh KumarDirector
- Kelly BeckExecutive Officer
- Uday B KompellaDirector
- Rasappa ArumughamExecutive Officer
- Vijay TammaraExecutive Officer
- Junge ZhangDirector
- Offering amount
- $395
- Amount sold
- $395
- First sale
- Apr 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$14.3MraisedMay 2020 · 6 investors · BiotechnologyRule 506(b)
▶$14.3MraisedMay 2020 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ramesh KumarDirector
- Rasappa ArumughamExecutive Officer
- Shankar MusunuriExecutive Officer, Director
- Kristen CastilloDirector
- Daniel JorgensenExecutive Officer
- Vijay TammaraExecutive Officer
- Junge ZhangDirector
- Kelly BeckExecutive Officer
- Suha TaspolatogluDirector
- Manish PottiDirector
- Uday B KompellaDirector
- Sanjay SubramanianExecutive Officer
- Prabhavathi FernandesDirector
- Offering amount
- $14.3M
- Amount sold
- $14.3M
- First sale
- Apr 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$30MraisedOct 2016 · 20 investors · Other Health CareRule 506(b)
▶$30MraisedOct 2016 · 20 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- John J. JohnsonDirector
- Joshua BaltzellDirector
- Kevin RakinDirector
- David GillDirector
- Adam GridleyExecutive Officer, Director
- Jonathan LieberDirector
- Garheng Kong, M.D., Ph.D.Director
- Michael LewisDirector
- Offering amount
- $30M
- Amount sold
- $30M
- Placement agents
- H.C. Wainwright & Co. LLC
- First sale
- Sep 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10.3MraisedJan 2014 · 17 investors · Other Health CareRule 506(b)
▶$10.3MraisedJan 2014 · 17 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Garheng Kong, M.D., Ph.DDirector
- John JohnsonDirector
- Peter GreenleafExecutive Officer, Director
- Joshua BaltzellDirector
- Kevin RakinDirector
- Michael LewisDirector
- Offering amount
- $20.6M
- Amount sold
- $10.3M
- First sale
- Dec 2013
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- Who are Histogenics's investors?
- Histogenics's investors include Sofinnova Ventures, FOUNDATION MEDICAL PARTNERS, Split Rock Partners.
- How much funding has Histogenics raised?
- Histogenics has disclosed $54.6M raised across 4 rounds.
- Where is Histogenics headquartered?
- Histogenics is headquartered in Waltham, US.